丁酸钠通过调节 SIRT1/AMPK 信号通路 对慢性肾衰竭大鼠肾功能的影响. (Chinese)

To investigate the effect of sodium butyrate (NaB) on renal function in rats with chronic renal failure (CRF) by regulating silent information regulator 1 (SIRT1)/adenosine monophosphate activated protein kinase (AMPK) signal pathway. A total of 72 SD rats were selected, and they were randomly divided into six groups (12 rats/group): control group, Model group, low dose NaB group (100 mg/kg), medium dose NaB group (200 mg/kg), high dose NaB group (400 mg/kg), and inhibitor group (400 mg/kg NaB+2 mg/kg SIRT1/AMPK pathway inhibitor EX527). The CRF rat model was established by feeding 0.5% adenine feed, and after successful modeling, the corresponding drugs were injected by gavage and intraperitoneal injection. The levels of 24 h urine protein (24 h U-pro), serum creatinine (Scr) and blood urea nitrogen (BUN) in rats were detected with the kits. The hematoxylin-eosin (HE) and Masson staining were used to observe the pathological changes of the kidney, and the collagen volume fraction (CVF) was calculated. The alizarin red staining and aortic calcium content determination were used to evaluate aortic calcification. The levels of interleukin (IL)-6, IL-β and tumor necrosis factor-alpha (TNF-α) in kidney tissue of rats in each group were detected by enzyme-linked immunosorbent assay (ELISA). The levels of CAT, MDA and ROS in kidney tissue of rats were detected with catalase (CAT), malondialdehyde (MDA) and reactive oxygen species (ROS) detection kits. The western blot was used to detect the expression of SIRT1/AMPK signal pathway and bone morphogenetic protein 2 (BMP2) and Runt-related transcription factor 2 (Runx2) protein in rats in each group. Compared with the control group, the kidney tissue of rats in the model group was severely damaged, collagen fiber deposition was significant, aortic calcification was serious, CAT activity, SIRT1, p-AMPK/AMPK expression levels were significantly decreased (P<0.05), while CVF, aortic calcium content and SCr, BUN, 24h U-pro, IL-6, IL-β, TNF-α, MDA, ROS and BMP2, Runx2 protein expression levels were significantly increased (P<0.05). Compared with the model group, the renal tissue damage, collagen fiber deposition area, aortic calcification, CVF, aortic calcium content, and SCr, BUN, 24h U-pro, IL-6, IL-β, TNF-α, MDA, ROS and BMP2, Runx2 protein expression levels in the low, middle, and high dose NaB groups were significantly decreased (P<0.05), while CAT activity, SIRT1, p-AMPK/AMPK expression were significantly increased (P<0.05). EX527, an inhibitor of SIRT1/AMPK pathway, could reduce the improvement of aortic calcification and renal function in CRF rats by high-dose NaB (P<0.05). NaB may play a role in improving the renal function of CRF rats by activating SIRT1/AMPK signal pathway and reducing renal tissue inflammation, oxidative stress injury, aortic calcification and renal fibrosis. [ABSTRACT FROM AUTHOR]

目的：探讨丁酸钠（NaB）通过调节沉默信息调节因子 1（SIRT1）/ 单磷酸腺苷活化蛋白激酶（AMPK）信号通路对慢性肾衰竭 （CRF）大鼠肾功能的影响。方法：选用 SD 大鼠 72 只，随机分为 6 组（12 只 / 组）：control 组、Model 组、NaB 低剂量组（100 mg/kg）、 NaB 中剂量组（200 mg/kg）、NaB 高剂量组（400 mg/kg）、抑制剂组（400 mg/kg NaB+2 mg/kg SIRT1/AMPK 通路抑制剂 EX527）；采 用饲喂 0.5%腺嘌呤饲料以建立 CRF 大鼠模型，建模成功后，灌胃和腹腔注射相应药物。使用试剂盒检测大鼠 24 h 尿蛋白（24 h U-pro）、血清肌酐（SCr）、尿素氮（BUN）水平；采用苏木精 - 伊红（HE）及 Masson 染色法观察肾脏病理改变，并计算胶原容积分数 （CVF）；采用茜素红染色法与主动脉钙含量测定评估主动脉钙化情况；采用酶联免疫吸附法（ELISA）检测各组大鼠肾脏组织白细 胞介素（IL）-6、IL-β、肿瘤坏死因子（TNF）-α 水平；采用过氧化氢酶（CAT）、丙二醛（MDA）、活性氧（ROS）检测试剂盒检测大鼠肾 脏组织中 CAT、MDA、ROS 水平；采用蛋白免疫印迹法（WB）检测各组大鼠 SIRT1/AMPK 信号通路及骨形态发生蛋白 2（BMP2）、 Runt 相关转录因子 2（Runx2）蛋白的表达。结果：与 control 组比较，Model 组大鼠肾脏组织损伤严重、胶原纤维沉积显著、主动脉 钙化严重，CAT 活性、SIRT1、p-AMPK/AMPK 表达水平显著降低（P<0.05），CVF、主动脉钙含量和 SCr、BUN、24 h U-pro、IL-6、IL-β、 TNF-α、MDA、ROS 水平及 BMP2、Runx2 蛋白表达水平显著升高（P<0.05）；与 Model 组比较，NaB 低、中、高剂量组大鼠肾脏组织 损伤减轻、胶原纤维沉积面积明显减少、主动脉钙化程度减轻，CVF、主动脉钙含量和 SCr、BUN、24 h U-pro、IL-6、IL-β、TNF-α、 MDA、ROS 水平及 BMP2、Runx2 蛋白表达水平显著降低（P<0.05），CAT 活性、SIRT1、p-AMPK/AMPK 表达水平显著升高（P<0. 05）；SIRT1/AMPK 通路抑制剂 EX527 可降低高剂量 NaB 对 CRF 大鼠主动脉钙化和肾功能的改善作用（P<0.05）。结论：NaB 可 能通过激活 SIRT1/AMPK 信号通路，减轻肾脏组织炎症、氧化应激损伤、主动脉钙化和肾纤维化，从而起到改善 CRF 大鼠肾功能 的作用。 [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)